Drug intelligence / Profile preview

CTX-4419

Development stage: Discontinued
Lead developer: Compass Therapeutics
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

CTX-4419 is a discontinued **biologic NK cell engager** developed by Compass Therapeutics for oncology, particularly **multiple myeloma**. It was designed as a **dual-function BCMA-targeting and NCR3-agonist molecule** intended to bind **B-cell maturation antigen** on malignant plasma cells while activating **natural cytotoxicity triggering receptor 3** on NK cells to promote NK-cell-mediated tumor killing. The program was positioned to address limitations associated with **CD16A polymorphism** that can affect some NK-cell-directed approaches, but its highest reported global R&D status is discontinued.

Targets

BCMA (B-cell maturation antigen)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))

Beyond the preview

Go deeper on CTX-4419.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTX-4419.